市場の成長要因は、個別化医療と精密医療の重要性の高まりにあります。慢性疾患の発生率の上昇と早期かつ正確な診断の必要性が、包括的な代謝分析の需要を煽る主な要因です。質量分析とNMR分光法の技術的進歩によって、データの精度と分析能力が向上し、市場の成長がさらに促進されます。さらに、製薬およびバイオテクノロジー分野での研究活動とコラボレーションの増加が市場を後押ししています。メタボロミクスとゲノミクスおよびプロテオミクスの統合は、ホリスティックヘルスソリューションへの応用も拡大し、将来の市場拡大を推進しています。
目次
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Metabolomics Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Metabolomics Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Metabolomics Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Metabolomics Market
10.1. Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Metabolomics Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Product and Services
11.3.1.1. Metabolomics Instruments
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2. Separation Tools
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3. Detection Tools
11.3.1.3.1. By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Application
11.3.2.1. Biomarker Discovery
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Drug Discovery
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Personalized Medicine
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.4. Toxicology Testing
11.3.2.4.1. By Value (USD Million) 2024-2034F
11.3.2.4.2. Market Share (%) 2024-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.5. Nutrigenomics
11.3.2.5.1. By Value (USD Million) 2024-2034F
11.3.2.5.2. Market Share (%) 2024-2034F
11.3.2.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.6. Functional Genomics
11.3.2.6.1. By Value (USD Million) 2024-2034F
11.3.2.6.2. Market Share (%) 2024-2034F
11.3.2.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.7. Other Applications
11.3.2.7.1. By Value (USD Million) 2024-2034F
11.3.2.7.2. Market Share (%) 2024-2034F
11.3.2.7.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Indication
11.3.3.1. Cancer
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Neurological Disorders
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Cardiovascular Diseases
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Inborn Errors of Metabolism
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Other
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2. Market Share (%) 2024-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.4. By End User
11.3.4.1. Contract Research Organization
11.3.4.1.1. By Value (USD Million) 2024-2034F
11.3.4.1.2. Market Share (%) 2024-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.2. Academic and Research Institutes
11.3.4.2.1. By Value (USD Million) 2024-2034F
11.3.4.2.2. Market Share (%) 2024-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.3. Pharmaceutical and Biotechnology Companies
11.3.4.3.1. By Value (USD Million) 2024-2034F
11.3.4.3.2. Market Share (%) 2024-2034F
11.3.4.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.4. Other End-users
11.3.4.4.1. By Value (USD Million) 2024-2034F
11.3.4.4.2. Market Share (%) 2024-2034F
11.3.4.4.3. Y-o-Y Growth (%) 2024-2034F
12. North America Metabolomics Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Product & Services
12.3.2. By Application
12.3.3. By Indication
12.3.4. By End User
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Metabolomics Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Product & Services
13.3.2. By Application
13.3.3. By Indication
13.3.4. By End User
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Metabolomics Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Product & Services
14.3.2. By Application
14.3.3. By Indication
14.3.4. By End User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Metabolomics Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Product & Services
15.3.2. By Application
15.3.3. By Indication
15.3.4. By End User
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Metabolomics Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Product & Services
16.3.2. By Application
16.3.3. By Indication
16.3.4. By End User
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Agilent Technologies Inc.
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. Thermo Fisher Scientific Inc.
18.3. Waters Corporation
18.4. Bruker Corporation
18.5. Bio-Rad Laboratories, Inc.
18.6. PerkinElmer Inc.
18.7. Metabolon, Inc.
18.8. Human Metabolome Technologies Inc.
18.9. Shimadzu Corporation
18.10. LECO Corporation
18.11. Evotec SE
18.12. Asuragen Inc.
18.13. GeneBio
18.14. Danaher Corporation
18.15. Sciex (a Danaher Company)
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
